Chronic use of proton pump inhibitors and the quantity of g, d, and ecl cells in the stomach / Uso crônico de inibidores de bomba de prótons e a quantidade de células g, d e ecl no estômago

ABSTRACT Background: Acid inhibition from chronic proton pump inhibitor use and a possible increase in gastrin can lead to changes in the regulation of hydrochloric acid production. However, it has not known whether such chronic use changes the presence of gastrin, delta, and enterochromaffin-like cells in the stomach or the relationship between gastrin and delta cells. Aim: To analyze the number of gastrin-producing gastrin cells, somatostatin-producing cells, and histamine-producing cells in patients who were chronic users of proton pump inhibitor, with or without related Helicobacter pylori infection. Methods: Biopsies from 105 patients, including 81 chronic proton pump inhibitor users (experimental group) and 24 controls, were processed immunohistochemically and subjected to counting of gastrin, delta, and enterochromaffin-like cells in high-magnification microscopic fields and in 10 glands. Results: Gastrin cell, delta cell, and enterochromaffin-like cells counts were similar across the groups and appeared to be unaffected by Helicobacter pylori infection. The ratio between gastrin cells and delta cells was higher in the chronic users of proton pump inhibitor group than in controls. Conclusion: Chronic users of proton pump inhibitor does not affect gastrin cell, delta cell, and enterochromaffin-like cell counts significantly, but may alter the ratio between gastrin cells and delta cells.

RESUMO Racional: A inibição ácida pelo uso crônico de inibidores de bomba de prótons e o possível aumento da gastrina podem ser seguidos de alterações na regulação da produção do ácido clorídrico. Ainda não está definido se o uso crônico altera a quantidade de células G, D e ECL no estômago ou a razão células G/D. Objetivo: Avaliar o número de células G - produtoras de gastrina -, células D - produtoras de somatostatina - e células ECL - produtoras de histamina -, em pacientes com uso crônico de inibidores de bomba de prótons, com ou sem infecção pelo Helicobacter pylori. Método: Trata-se de estudo retrospectivo avaliando 105 pacientes, 81 usadores crônicos de inibidores de bomba de prótons e 24 controles, através de biópsias com contagem das células G, D e ECL por estudo imunoistoquímico, de forma quantitativa onde havia maior número de células positivas por campo microscópico de grande aumento e em 10 glândulas. Resultados: Não houve diferença estatística comparando-se o número de células G, D e ECL. A razão entre as células G e D foi maior nos pacientes usadores crônicos de inibidores de bomba de prótons. Conclusão: O uso crônico de inibidores de prótons parece não interferir na contagem das células G, D e ECL, porém, interfere na razão entre as células G e D.

Erradicación de Helicobacter pylori en pacientes con dispepsia funcional / Helicobacter pylori eradication in patients with functional dyspepsia

La dispepsia constituye un motivo de consulta frecuente en atención primaria. A propósito de un paciente con diagnóstico de dispepsia funcional, la autora se plantea si el tratamiento de erradicación del Helicobacter pylori podría mejorar los síntomas. Luego de una búsqueda rápida se encontró evidencia que señala que el tratamiento de la infección por este germen podría ser beneficiosa para aliviar los síntomas de la dispepsia funcional a largo plazo, aunque con mayor riesgo de efectos adversos, por lo que otros tratamientos alternativos continúan siendo ser una opción válida en el manejo de los pacientes con este problema de salud. (AU)

Evaluation of Prevalence of the Metabolic Syndrome: In the Kirkuk Hospitals Reviewers from Employees Associated with H. Pylori AB Test as a Case Study

The metabolic syndrome (MetS) or insulin resistance syndrome is widespread and multi-factorial disorder. This article aims to assess and observe samples with the MetS to start efforts to take the proper treatments to minimize the risk of cardiovascular diseases. Additionally, we evaluate the association of Helicobacter pylori (H. Pylori) Ab tests with MetS. To meet this goal, 350 reviewers of K1 Hospital are participated in this work for six months from October 2016 to March 2017. The patients (N=350) are divided into two groups, a group subjects with MetS (N=109), whereas the latter is without MetS (N=241). A venous blood sample is taken after 8 hours of fasting to measure fasting blood glucose, H. Pylori Ab test and other required biochemical assays. Additionally, blood pressure (BP), Body Mass Index (BMI) (i.e. weight and height), and waist circumference are measured. The assays revealed that the frequency of MetS is 31.1% as per the modified National Cholesterol Education Program Adult Treatment Panel III (NCEP: ATPIII) criteria. Furthermore, a statistically significant age (p=0.02) corresponded higher rate of MetS cases is larger than 40 years old (i.e. 69%). Moreover, BMI recorded as (27.6 ± 4.4 vs 31.4 ± 4.5, p <0.001), height (169 ± 8.4 vs 168.1 ± 8.5, p ≤ 0.11), weight (78.8 ± 12.3 vs 88.6 ± 13.2, p<0.01) and waist circumference (83.3 ± 16.1 vs 96.3 ± 11.6, p<0.001). Besides, BP showed positively correlation with systolic (120.3 ± 10.6 vs 130.6 ± 10.8, p<0.04) and diastolic (70.9 ± 0.9 vs 80.8 ± 10, p<0.01). The biochemical assays for employees with and without MetS are mean values of fasting Serum glucose (5.3 ± 1.4 vs 7.5 ± 3.2, p ≤ 0.001). The highest average total cholesterol recorded as (4.3 ± 1.3 vs 4.9 ± 1.3, p ≤ 0.001), serum triglyceride (2 ± 1.5 vs 2.8 ± 1.2, p ≤ 0.001) and lower HDL levels (1.2 ± 0.5 vs 0.8 ± 0.1, p ≤ 0.001). Accordingly, the results showed that H. Pylori infection is associated significantly with metabolic syndrome. In consequence, the outcome demonstrated high rates of obesity and overweight in MetS cases

Helicobacter pylori: qué debemos saber en el año 2018. Revisión de la evidencia y nuevas recomendaciones de tratamiento / Helicobacter pylori: what should we know in the year 2018. Review of the evidence and new treatment recommendations

Helicobacter pylori (HP) is the most widely chronic human infection around the world, and the main risk factor for the development of gastric cancer. Our country has high rates of this neoplasia and a high prevalence of HP infection. Even both have fallen in the last year, is a major concern to diagnose the population infected with HP in early stages, before the development of premalignant lesions and properly eradicate this infection. In this review, we discussed the different methods for the diagnosis of HP and factors that change positivity as the use of proton pump inhibitors. Also, we discussed the factors to be considered in the choice of the treatment, like local resistance to antibiotics, specially clarithromycin. In the last years has been documented in Chile a significant increase in resistance to clarithromycin, from 20 to 46%, which predicts inadequate effectiveness for the classic triple therapy. As the result of the previous analysis we discussed new possible therapies, including bismuth quadruple therapy and concomitant therapy. (AU)

O mel-derivado de Lactobacillus rhamnosus alivia a infecção gastro-intestinal induzida pelo Helicobacter pylori-e inflamação gástrica em C57Bl/6 ratos: um estudo imuno-histológico / Honey-derived lactobacillus rhamnosus alleviates helicobacter pylori-induced gastro-intestinal infection and gastric inflammation in c57bl/6 mice: an immuno-histologic study

ABSTRACT BACKGROUND: Helicobacter pylori (H. pylori) has been introduced by since 1983 by Marshal and Warren to play the main role in the pathophysiology of gastritis and gastric ulcers. Almost half of the world population1 is infected by H. pylori. Current therapeutic regimen against H. pylori includes the use of a proton pump inhibitor plus two or more antibiotics. However, the efficacy of this regimen is decreasing mainly due to antibiotic resistance and side effects of medications. This fact has resulted in public interest in other therapeutic options and the role of probiotics merits special attention in this regard. OBJECTIVE: This study aims to evaluate the efficacy of honey-derived Lactobacillus rhamnosus on H. pylori-induced gastric inflammation and gastro-intestinal infection in C57BL/6 Mice. METHODS: The 24 C57BL/6 Mice were randomly divided into three groups of eight mice each. All the mice were fed with 1cc suspension containing 5*1010 CFU/ mL of ATCC43504 strains of H. pylori for 3 consecutive days, twice daily via polyethylene gavage tubes. At the end of 4th week, infection with H. pylori was confirmed with stool Ag (ELISA) and following sacrifice of one mouse from each group, histopathologic study confirmed gastritis. The groups were subjected to different therapies as stated, 1: without Bismuth (Bi), Omeprazole (Om) and L. rhamnosus prescription, 2: Bi, Om and Clarithromycin (Cl) and 3: Bi, Om plus 1cc of suspension of 109 CFU/mL of L. rhamnosus. After 2 weeks, the stool was analyzed for Ag and the mice were sacrificed for evaluation of histopathologic changes. RESULTS: Treatment with L. rhamnosus group provided Zero titer of stool Ag and was associated with improved gastric inflammation in all subjects, similar to the clarithromycin group. CONCLUSION: Honey-derived L. rhamnosus probiotics provides similar results as clarithromycin in terms of improvement of H. pylori infection and gastritis in C57BL/6 Mice model, without its cons of antibiotic resistance.

RESUMO CONTEXTO: O Helicobacter pylori (H. pylori) foi reconhecido em 1983 por Marechal e Warren como protagonista principal na fisiopatologia de gastrite e úlceras gástricas. Quase metade da população mundial está infectada por H. pylori. O regime terapêutico atual contra H. pylori inclui o uso de um inibidor da bomba de prótons associada a dois ou mais antibióticos. No entanto, a eficácia deste regime está diminuindo principalmente devido à resistência aos antibióticos e efeitos colaterais de medicamentos. Este fato resultou no interesse público em outras opções terapêuticas e o papel dos probióticos merece atenção especial a este respeito. OBJETIVO: Este estudo visa avaliar a eficácia do mel-derivado do Lactobacillus rhamnosus na inflamação gástrica e infecção gastrointestinal H. pylori-induzida em camundongos C57Bl/6. MÉTODOS: Vinte e quatro camundongos C57Bl/6 foram divididos aleatoriamente em três grupos de oito camundongos cada. Todos os ratos foram alimentados com suspensão de 1cc contendo 5*1010 UFC/mL de cepas ATCC43504 de H. pylori por 3 dias consecutivos, duas vezes por dia através de gavagem por tubos de polietileno. No final da 4ª semana, a infecção com H. pylori foi confirmada pelo antígeno fecal (ELISA) e após o sacrifício de um rato de cada grupo, o estudo histopatológico confirmou gastrite. Os grupos foram submetidos a diferentes terapias, como indicado, 1: sem prescrição de bismuto (BI), Omeprazol (Om) e L. rhamnosus, 2: Bi, Om e claritromicina (CL) e 3: Bi, Om mais 1cc de suspensão de 109 UFC/mL de L. rhamnosus. Após 2 semanas, as fezes foram analisadas para o antígeno e os ratos foram sacrificados para a avaliação das alterações histopatológicas. RESULTADOS: O tratamento com o grupo L. rhamnosus forneceu o título zero de antígeno e foi associado com a inflamação gástrica melhorada em todos os camundongos, similar ao grupo claritromicina. CONCLUSÃO: O probiótico mel-derivado L. rhamnosus fornece resultados semelhantes ao da claritromicina em termos de melhoria da infecção H. pylori e gastrite em C57Bl/6 camundongos modelos, sem os inconvenientes de resistência aos antibióticos.

Upper gastrointestinal endoscopy applied in pediatrics: endoscopic and histological findings, including Helicobacter pylori / Endoscopia digestiva alta aplicada em pediatria: hallazgos endoscópicos e histológicos incluyendo al Helicobacter pylory

Objective: To present and discuss the endoscopic and histological results, as well as the incidence of Helicobacter pylori and other diseases, indications and characteristics of upper digestive endoscopies performed in children. Material and methods: Twenty-five endoscopies were performed in children aged six months to 11 years (mean 7.69 years), from February 2013 to January 2016. In 200 patients, endoscopies were diagnostic and serial biopsies were performed (esophagus, stomach and duodenum), in 120 of them. Results: The indication of endoscopy was diagnosed in 88.89% of the patients, and in 26 patients, a therapeutic procedure was performed. The most frequent endoscopic findings were esophagitis in 49 patients, gastritis in 84 and duodenitis in 16 patients. Four duodenal ulcers were diagnosed. In the therapeutic endoscopies, six gastrostomies were performed, 14 foreign body withdrawals, five nasoenteral tube passages and esophageal dilatation. The H. pylori survey was performed by anatomopathological method and was positive in 26 (13%) of the 200 patients in whom it was searched. Conclusion: pediatric endoscopy is an important niche of the digestive endoscopy, where it is important to emphasize the relevance of the institutional structure that performs these procedures, in order to conduct them safely, being able to treat possible and feasible complications

Objetivo: Presentar y discutir los hallazgos endoscópicos e histológicos, así como la incidencia de Helicobacter pylori y otras enfermedades, indicaciones y características de endoscopia digestiva alta realizada en niños. Material y métodos: Fueron realizadas 225 endoscopias en niños de seis meses a 11 años (media de 7,69 años) a partir de febrero de 2013 hasta enero de 2016. En 200 pacientes, en las endoscopias diagnósticas se llevan a cabo biopsias seriadas (esófago, estómago y duodeno) en 120 de ellos. Resultados: La indicación de endoscopia fue diagnóstica en el 88,89% de los pacientes y en 26 pacientes se realizaron un procedimiento terapéutico. Los hallazgos endoscópicos más frecuentes fueron esofagitis en 49 pacientes, gastritis y duodenitis 84 y en 16 pacientes se diagnosticaron cuatro úlceras duodenales. En endoscopias terapéuticas fueron realizadas seis gastrostomías, catorce extracciones de cuerpos extraños, cinco pasajes de sonda nasogástrica y una dilatación esofágica. El estudio de H. pylori se realizó por el método histopatológico y fué positivo en 26 (13%) de 200 pacientes en los que se han buscado. Conclusión: La endoscopía pediátrica es un nicho importante de la endoscopía digestiva donde es importante enfatizar la relevancia de la estructura institucional que realiza estos procedimientos para conducirlos con seguridad y ser capaces de tratar las complicaciones posibles

Erradicación de Helicobacter pylori con terapia triple estándar de primera línea / Helicobacter pylori eradication with standard first-line triple therapy

La infección por Helicobacter pylori es una de las infecciones crónicas más comunes a nivel mundial y causa importante de enfermedad péptica y cáncer gástrico. Infecta al 50% de la población adulta con mayor prevalencia en América Central/Sur y Asia y al menos dos veces mayor en poblaciones con alta incidencia de cáncer gástrico. Los objetivos de esta investigación fueron identificar la tasa de erradicación de H. pylori con terapia triple estándar y las posibles características asociadas a su erradicación. Se estudió a 119 pacientes con diagnóstico de infección por H. pylori, seleccionados en forma consecutiva de la consulta externa de Gastroenterología del Hospital General San Juan de Dios. Se realizó endoscopia diagnóstica y toma de biopsia gástrica. Se dio terapia triple estándar con lansoprazol, amoxicilina y claritromicina durante 10 días, seguido de 30 días con lansoprazol. Seis semanas después de completado el tratamiento se evaluó el antígeno de H. pylori en heces para determinar si hubo erradicación. La edad promedio de los participantes fue 49.0 años, 81.5% mujeres, 85.7% de área urbana, el síntoma más común fue dispepsia en 86.6%. En el examen post tratamiento el 89.9%, IC 95% [83.0, 94.7] presentó antígeno en heces negativo. No se encontró asociación entre las características de los pacientes con la respuesta al tratamiento. En conclusión, la respuesta a la terapia triple de primera línea se encuentra dentro del rango aceptable para continuar con ese esquema, pero debe mantenerse una evaluación constante por la presencia de posible resistencia.

Infection by Helicobacter pylori is one of the most common chronic infections worldwide and an important cause of peptic disease and gastric cancer. It infects 50% of the adult population with the highest prevalence in Central / South America and Asia and at least twice as high in populations with a high incidence of gastric cancer. The objectives of this research were to identify the eradication rate of H. pylori after first line standard triple therapy and the possible characteristics associated with its eradication. It was studied 119 patients with a diagnosis of H. pylori infection, selected consecutively from the outpatient department of Gastroenterology of the San Juan de Dios General Hospital. Diagnostic endoscopy and gastric biopsy was performed. Standard triple therapy was given with lansoprazole, amoxicillin and clarithromycin for 10 days, followed by 30 days with lansoprazole. Six weeks after the treatment was completed, the H. pylori antigen in feces was evaluated to determine if there was eradication. The average age of the participants was 49.0 years, 81.5% women, 85.7% of urban area, the most common symptom was dyspepsia in 86.6%. In the post-treatment examination 89.9%, 95% CI [83.0, 94.7] presented negative antigen in feces. No association was found between the characteristics of the patients with the response to treatment. In conclusion, the response to first line triple therapy is within the acceptable range to continue with this scheme, but a constant evaluation must be maintained due to the presence of possible resistance.

Mexican consensus on dyspepsia / Consenso mexicano sobre la dispepsiaMexican consensus on dyspepsia

Desde la publicación de las guías de dispepsia 2007 de la Asociación Mexicana de Gastroenterología ha habido avances significativos en el conocimiento de esta enfermedad. Se realizó una revisión sistemática de la literatura en PubMed (01/2007 a 06/2016) con el fin de revisar y actualizar las guías 2007 y proporcionar nuevas recomendaciones basadas en evidencia. Se incluyeron todas las publicaciones en español e inglés, de alta calidad. Se redactaron enunciados que fueron votados utilizando el método Delphi. Se estableció la calidad de la evidencia y la fuerza de las recomendaciones según el sistema GRADE para cada enunciado. Treinta y un enunciados fueron redactados, votados y calificados. Se informan nuevos datos sobre definición, clasificación, epidemiología y fisiopatología. La endoscopia debe realizarse en dispepsia no investigada cuando hay datos de alarma o falla al tratamiento. Las biopsias gástricas y duodenales permiten confirmar infección por Helicobacter pylori y excluir enfermedad celiaca, respectivamente. Establecer una fuerte relación médico-paciente, cambios en la dieta y en el estilo de vida son útiles como medidas iniciales. Los bloqueadores H2, inhibidores de la bomba de protones, procinéticos y fármacos antidepresivos son efectivos. La erradicación de H. pylori puede ser eficaz en algunos pacientes. Con excepción de Iberogast y rikkunshito, las terapias complementarias y alternativas carecen de beneficio. No existe evidencia con respecto a la utilidad de prebióticos, probióticos o terapias psicológicas. Los nuevos enunciados proporcionan directrices basadas en la evidencia actualizada. Se presenta la discusión, el grado y la fuerza de la recomendación de cada uno de ellos.

Abstract Since the publication of the 2007 dyspepsia guidelines of the Asociación Mexicana de Gastroenterología, there have been significant advances in the knowledge of this disease. A systematic search of the literature in PubMed (01/2007 to 06/2016) was carried out to review and update the 2007 guidelines and to provide new evidence-based recommendations. All high-quality articles in Spanish and English were included. Statements were formulated and voted upon using the Delphi method. The level of evidence and strength of recommendation of each statement were established according to the GRADE system. Thirty-one statements were formulated, voted upon, and graded. New definition, classification, epidemiology, and pathophysiology data were provided and include the following information: Endoscopy should be carried out in cases of uninvestigated dyspepsia when there are alarm symptoms or no response to treatment. Gastric and duodenal biopsies can confirm Helicobacter pylori infection and rule out celiac disease, respectively. Establishing a strong doctor-patient relationship, as well as dietary and lifestyle changes, are useful initial measures. H2-blockers, proton-pump inhibitors, prokinetics, and antidepressants are effective pharmacologic therapies. H. pylori eradication may be effective in a subgroup of patients. There is no evidence that complementary and alternative therapies are beneficial, with the exception of Iberogast and rikkunshito, nor is there evidence on the usefulness of prebiotics, probiotics, or psychologic therapies. The new consensus statements on dyspepsia provide guidelines based on up-to-date evidence. A discussion, level of evidence, and strength of recommendation are presented for each statement. © 2017 Asociacion Mexicana de Gastroenterologiia.

Prise en charge de l'infection à Helicobacter pylori dans le contexte de la Ville Province de Kinshasa

Contexte et objectifs. L?infection bactérienne à Helicobacter Pylori constitue un des problèmes majeurs de santé publique en Afrique où elle atteindrait plus de 90% des adultes dans certaines régions. En République Démocratique du Congo comme dans la plupart de pays de la région des Grands lacs, la prise en charge de l?infection à HP n?est pas encore codifiée. L?objectif de la présente étude était de proposer un schéma accessible financièrement et adapté des recommandations des sociétés savantes.Méthodes. Partant de la revue fournie de la littérature sur la question notamment sur les méthodes diagnostiques et contrôle d?éradication et les protocoles de traitement de l?infection à HP, nous avons retenu les recommandations diagnostiques et thérapeutiques les plus pertinentes afin de les adapter à notre environnement de travail sous forme d?un protocole à proposer au consensus des participants.Résultats. L?infection à HP est une entité nosologique qui a des manifestations cliniques liées au stade auquel on débute sa prise en charge. L?infection est fréquente et jouerait un rôle important dans les survenues des lésions précancéreuse et cancéreuse d?où l?intérêt de promouvoir un management codifié aussi bien diagnostique que thérapeutique Les méthodes diagnostiques les plus pertinentes et les mieux adaptées à notre milieu sont celles invasives obtenues lors de l?examen endoscopique par biopsie (le test rapide à l?uréase) et celle non invasive (la détection immunologique des antigènes bactériens dans les selles). Le traitement adapté est celui accessible financièrement : la quadrithérapie sans bismuth : séquentielle, concomitante ou hybride à savoir l?association d?un Inhibiteur de la pompe à protons (IPP), de l?Amoxycilline, la Clarythromycine et le Métronidazole pendant 10 à 14 jours.Conclusion. Le traitement standard a été remplacé par quadrithérapie sans bismuth. Le défi majeur est celui d?adapter et d?adopter le meilleur schéma de traitement disponible et de continuer à optimiser les thérapies pour surmonter avec succès la résistance croissante de l?HP. Une étude prospective et analytique sur la sensibilité de le HP aux antibiotiques usuels pour la mise au point d?un traitement efficace et simple adapté à notre environnement est à envisager. La recherche d?un vaccin avec un succès partiel déjà atteint ne devrait pas être abandonnée

Terapia clásica frente a terapia secuencial en la erradicación de la infección por Helicobacter pylori / Classical therapy versus sequential therapy in the eradication of Helicobacter pylori infection

Introducción: en el año 1983 se descubre el Helicobacter pylori, lo cual abrió un nuevo campo en la atención de las enfermedades que este causaba así como en el tratamiento para erradicar esta bacteria. Objetivo: comparar la eficacia de la terapia clásica respecto a la terapia secuencial en la erradicación de la infección por Helicobacter pylori. Método: se realizó un estudio analítico aleatorio en el Centro de Investigaciones Médico Quirúrgico, entre enero del 2013 y mayo del 2015. Se estudiaron 160 pacientes, según los criterios de inclusión, los que fueron ubicados en dos grupos: Grupo A, con 80 pacientes, para la terapia secuencial y Grupo B, con 80 pacientes, para la terapia clásica. Resultados: el promedio de edad de ambos grupos fue de 46,0 ± 14,3 años. El promedio de edad de los pacientes que recibieron terapia clásica fue de 46,9 ± 14,6 años mientras que el promedio en el grupo de la terapia secuencial fue de 45,2 ± 14,1 años; no hubo diferencias significativas entre ambos grupos (p= 0,770) en cuanto a la edad ni al sexo. La gastritis eritematosa antral fue el diagnóstico endoscópico más identificado (24,4 por ciento) mientras que en el histológico fue la gastritis crónica antral moderada (36,9 por ciento). El 93,7 por ciento de los pacientes que recibieron la terapia clásica erradicaron la infección por Helicobacter pylori lo que representó una diferencia de erradicación respecto a la terapia secuencial. Conclusiones: la terapia clásica fue más eficaz que la terapia secuencial en la erradicación del Helicobacter pylori(AU)

Introduction: Helicobacter pylori was discovered in 1983, opening a new field in the management of diseases it causes as well as the treatment for the eradication of this bacterium. Objective: compare the efficacy of classical treatment compared with sequential therapy in the eradication of Helicobacter pylori infection. Method: a randomized analytical study was conducted at the Center for Medical Surgical Research from January 2013 to May 2015. A hundred sixty (160) patients were studied according to the inclusion criteria and they were divided into two groups: Group A, with 80 patients for sequential therapy and group B with 80 patients to conventional therapy. Results: the average age of both groups was 46.0 ± 14.3 years. For patients who received conventional therapy the average age was 46.9 ± 14.6 years while the sequential therapy group was 45.2 ± 14.1 years with no significant differences in both groups (p = 0.770), nor were significant differences for sex. Erythematous antral gastritis was the most identified endoscopic diagnosis in 24.4 percent while moderate chronic gastritis antral was the most identified histologic diagnosis in 36.9 percent. 93.7percent of patients who received conventional therapy eradicated Helicobacter pylori infection, representing a difference eradication regarding sequential therapy. Conclusions: classical therapy was more effective than sequential therapy in the eradication of Helicobacter pylori(AU)

Eficacia de sutura y epiploplastia con tratamiento médico posterior en la úlcera perforada / Epiploplasty and Suture Efficiency Using Further Medical Treatment in Perforated Ulcer

Introducción: la sutura y epiploplastia de la úlcera perforada con tratamiento médico posterior para erradicar el Helicobacter pylori, ha disminuido la recurrencia de la úlcera péptica, lo cual renueva el interés en este proceder ante las técnicas definitivas. Objetivos: determinar la eficacia a mediano plazo de este proceder en pacientes operados de úlcera péptica perforada. Métodos: se realizó un estudio observacional analítico en el Hospital Universitario "Manuel Ascunce Domenech" de Camagüey, desde enero de 2010 hasta diciembre de 2013. El estudio estuvo conformado por los pacientes operados de úlcera perforada con más de un año de evolución (45 casos). Los datos obtenidos se procesaron mediante el paquete estadístico SPSS para Windows versión 15.0, con técnica estadística de comparación de la prueba de hipótesis de proporciones en una computadora Pentium IV. Resultados: el sexo más afectado fue el masculino y predominó en la cuarta y quinta décadas de la vida. La localización más frecuente de la perforación fue duodenal y la mayoría, menores de 1 cm. Las complicaciones posoperatorias más frecuentes fueron las infecciones respiratorias. El tabaquismo y la ingestión de café fueron los factores de riesgo actuales más frecuentes. La mayoría de los pacientes recibieron tratamiento médico completo en el posoperatorio, con buenos resultados de acuerdo a la clasificación de Visick y en la endoscopia realizada, donde solo una paciente presentó enfermedad ulcerosa. Conclusiones: se comprobó que la sutura y epiploplastia de la úlcera perforada con tratamiento médico posterior completo es eficaz a mediano plazo(AU)

Introduction: suture and epiploplasty of perforated ulcer using further medical treatment for helicobacter pylori eradication has decreased recurrence of peptic ulcer, renewing interest in this proceeding in contrast to final techniques. Objective: determine the medium term efficacy of this procedure in patients undergoing surgery for perforated peptic ulcer. Methods: an observational study was conducted at Manuel Ascunce Domenech University Hospital in Camagüey, from January 2010 to December 2013. The study consisted of patients operated on for perforated ulcer over a year (45 cases). The obtained data were processed using SPSS for Windows version 15.0, with statistical technique of comparing the proportions hypothesis test on a Pentium IV computer. Results: the most affected patients were male aging forty and fifty. The most frequent location was duodenal perforation and most of them less than 1 cm. The most frequent postoperative complications were respiratory infections. Smoking habits and coffee intake were the most common risk factors. Most patients received full medical treatment in the postoperative period, with good results according to Visick classification and the endoscopy, where only one patient had ulcer disease. Conclusions: suture and perforated ulcer epiploplasty with subsequent full medical treatment, definitively, cure patients(AU)

comparison between hybrid therapy and standard triple therapy for helicobacter pylori eradication in patients with uremia: a randomized clinical trial

Background: The prevalence of peptic ulcer disease in hemodialysis patients is more than the general population. They are also more prone to complications including upper gastrointestinal bleeding. The aim of this study was to compare the efficacy of 14 days hybrid regimen with 14 days triple therapy for Helicobacter pylori [H. pylori] eradication in hemodialysis patients

Methods: Forty hemodialysis patients with naïve H.pylori infection were randomized to receive either hybrid regimen [pantoprazole 40 mg + amoxicillin 500 mg, both twice a day during the first 7 days, followed by pantoprazole 40 mg + amoxicillin 500 mg + clarithromycin 500 mg + tinidazole 500 mg, all twice a day, for the second 7 days, or standard triple therapy including pantoprazole 40 mg, clarithromycin 500 mg, and amoxicillin 500 mg, all twice a day for 14 days. H.pylori eradication was assessed by fecal H.pylori antigen test 8 weeks after the treatment

Results: All the patients completed the study. According to both intention to treat and per-protocol analyses, H.pylori eradication rates were 100% [95% confidence interval [CI]: 100] in those who received hybrid therapy and 70% [95% CI: 69.4 - 70.8] in those who were treated by standard triple therapy [p=0.02]. Severe adverse effects were not reported by any patient; however, mild adverse effects were more frequent in those who received standard triple therapy [p<0.05]

Conclusion: Hybrid regimen could achieve ideal H.pylori eradication rates with low rates of adverse effects

Effects of clarithromycin-containing quadruple therapy on helicobacter pylori eradication after nitroimidazole-containing quadruple therapy failure

Background: Several large clinical trials and meta-analyses have shown about 20% failure to eradicate Helicobacter pylori [H.pylori], necessitating investigations for second-line treatments. The aim of this study was to evaluate the effects of clarithromycin-containing quadruple regimen after nitroimidazole-containing quadruple therapy failure

Methods: Thirty two patients who had failed 10-day H.pylori treatment with omeprazole, amoxicillin, bismuth subcitrate, and metronidazole [OABM] regimen and 31 patients who had failed 10-day treatment with omeprazole, amoxicillin, bismuth subcitrate, and furazolidone [OAMF] regimen entered the study. They all received omeprazole [20 mg], amoxicillin [1 gr], bismuth subcitrate [240 mg] and clarithromycin [500 mg] twice a day for 10 days. Eight weeks after treatment, H. pylori eradication was assessed by 14C-urea breath test

Results: Totally 61 patients completed the study. According to intention to treat [ITT] analysis, eradication rates by second-line OABC regimen were 84.37% [95% CI= 71.7-96.9%] in OABM group and 77.41% [95% CI= 62.71-92.11%] in OABF group [p=0.756]. Per-protocol [pp] eradication rates were 87.09% [95% CI= 75.2-98.8%] and 82.75% [95% CI= 79.4-96%], respectively [p=0.638]. Also the cumulative eradication rates by OABC regimen were 80.9% [95% CI= 71.2-90.6%] and 85% [95% CI= 75.9-94%] according to ITT and PP analyses, respectively. Severe side effects were reported in 3.1% of the patients

Conclusion: Regarding ideal eradication rate [>80%] and very low adverse effects, it seems that clarithromycin-containing quadruple therapy can be an encouraging regimen after nitroimidazole-containing regimen failure

Efficacy of a quadruple therapy regimen for Helicobacter pylori eradication after partial gastrectomy

We aimed to evaluate the effectiveness and safety of bismuth-containing quadruple therapy plus postural change after dosing for Helicobacter pylori eradication in gastrectomized patients. We compared 76 gastric stump patients with H. pylori infection (GS group) with 50 non-gastrectomized H. pylori-positive patients who met the treatment indication (controls). The GS group was divided into GS group 1 and GS group 2. All groups were administered bismuth potassium citrate (220 mg), esomeprazole (20 mg), amoxicillin (1.0 g), and furazolidone (100 mg) twice daily for 14 days. GS group 1 maintained a left lateral horizontal position for 30 min after dosing. H. pylori was detected using rapid urease testing and histologic examination of gastric mucosa before and 3 months after therapy. Mucosal histologic manifestations were evaluated using visual analog scales of the updated Sydney System. GS group 1 had a higher prevalence of eradication than the GS group 2 (intention-to-treat [ITT]: P=0.025; per-protocol [PP]: P=0.030), and the control group had a similar prevalence. GS group 2 had a lower prevalence of eradication than controls (ITT: P=0.006; PP: P=0.626). Scores for chronic inflammation and activity declined significantly (P<0.001) 3 months after treatment, whereas those for atrophy and intestinal metaplasia showed no significant change. Prevalence of adverse reactions was similar among groups during therapy (P=0.939). A bismuth-containing quadruple therapy regimen plus postural change after dosing appears to be a relatively safe, effective, economical, and practical method for H. pylori eradication in gastrectomized patients.

Guía de práctica clínica para el diagnóstico y tratamiento de la infección por Helicobacter pylori en adultos / Clinical Practice Guideline for the Diagnosis and Management of Adult Patients with Helicobacter pylori Infection

Objetivo: brindar una guía de práctica clínica basada en la evidencia más reciente para el diagnóstico y tratamiento de la infección por Helicobacter pylori teniendo en cuenta la efectividad y seguridad de las intervenciones dirigidas a pacientes, personal asistencial, administrativo y entes gubernamentales de cualquier servicio de atención en Colombia. Materiales y métodos: esta guía fue desarrollada por un equipo multidisciplinario con apoyo de la Asociación Colombiana de Gastroenterología, el Grupo Cochrane ITS y el Instituto de Investigaciones Clínicas de la Universidad Nacional de Colombia. Se desarrollaron preguntas clínicas relevantes y se realizó la búsqueda de guías nacionales e internacionales en bases de datos especializadas. Las guías existentes fueron evaluadas en términos de calidad y aplicabilidad; una de ellas cumplió los criterios de adaptación, por lo que se decidió adaptar 4 preguntas clínicas y construir 10 de novo. El Grupo Cochrane realizó la búsqueda sistemática de la literatura. Las tablas de evidencia y recomendaciones fueron realizadas con base en la metodología GRADE. Las recomendaciones de la guía fueron socializadas en una reunión de expertos con entes gubernamentales y pacientes. Resultados: se desarrolló una guía de práctica clínica basada en la evidencia para el diagnóstico y tratamiento de la infección de Helicobacter pylori en Colombia. Conclusiones: la erradicación de H. pylori, curará las ulceras pépticas asociadas al mismo, la gastritis crónica sin atrofia o metaplasia intestinal y contribuirá a disminuir el riesgo de cáncer gástrico, que es la primera causa de muerte por cáncer en Colombia.

Objective: To provide a clinical practice guideline with the latest evidence for diagnosis and treatment of Helicobacter pylori infection for patients, caregivers, administrative and government bodies at all levels of care in Colombia. Materials and Methods: This guide was developed by a multidisciplinary team with the support of the Colombian Association of Gastroenterology, Cochrane STI Group and Clinical Research Institute of the Universidad Nacional de Colombia. Relevant clinical questions were developed and the search for national and international guidelines in databases was performed. Existing guidelines were evaluated quality and applicability. One guideline met the criteria for adaptation, so the group decided to adapt 4 clinical questions and to develop 10 de novo clinical questions. Systematic literature searches were conducted by the Cochrane Group. The tables of evidence and recommendations were made based on the GRADE methodology. The recommendations of the guide were socialized in a meeting of experts with government agencies and patients. Results: An evidence-based Clinical Practice Guidelines for the diagnosis and treatment of Helicobacter pylori infection was developed for the Colombian context. Conclusions: The opportune detection and appropriate management of Helicobacter pylori would contribute to the burden of the disease in Colombia and its associated diseases.

3rd Brazilian consensus on Helicobacter pylori / 3º Consenso Brasileiro para Estudo do Helicobacter pylori

Significant progress has been obtained since the Second Brazilian Consensus Conference on Helicobacter pylori Infection held in 2004, in São Paulo, SP, Brazil, and justify a third meeting to establish updated guidelines on the current management of H. pylori infection. The Third Brazilian Consensus Conference on H pylori Infection was organized by the Brazilian Nucleus for the Study of Helicobacter, a Department of the Brazilian Federation of Gastroenterology and took place on April 12-15, 2011, in Bento Gonçalves, RS, Brazil. Thirty-one delegates coming from the five Brazilian regions and one international guest, including gastroenterologists, pathologists, epidemiologists, and pediatricians undertook the meeting. The participants were allocated in one of the five main topics of the meeting: H pylori, functional dyspepsia and diagnosis; H pylori and gastric cancer; H pylori and other associated disorders; H pylori treatment and retreatment; and, epidemiology of H pylori infection in Brazil. The results of each subgroup were submitted to a final consensus voting to all participants. Relevant data were presented, and the quality of evidence, strength of recommendation, and level of consensus were graded. Seventy per cent and more votes were considered as acceptance for the final statement. This article presents the main recommendations and conclusions to guide Brazilian doctors involved in the management of H pylori infection.

Os avanços significativos ocorridos desde o Segundo Consenso Brasileiro sobre H. pylori realizado em 2004, em São Paulo, justificam este terceiro consenso. O evento foi organizado pelo Núcleo Brasileiro para Estudo do Helicobacter, departamento da Federação Brasileira de Gastroenterologia, tendo sido realizado em Bento Gonçalves, RS, nos dias 12 a 15 de abril de 2011. Contou com a participação de 30 delegados provenientes das cinco regiões brasileiras e um convidado internacional, incluindo gastroenterologistas, patologistas, epidemiologistas e pediatras. Os participantes foram alocados em um dos cinco subgrupos do evento, a saber: Helicobacter pylori, dispepsia funcional e diagnóstico; Helicobacter pylori e câncer gástrico; Helicobacter pylori e afecções não-gastroduodenais; Helicobacter pylori, tratamento e retratamento, e, epidemiologia da infecção por Helicobacter pylori no Brasil. Após extensa discussão, todas as recomendações e conclusões emanadas tinham definidas a força da recomendações e seu grau de evidência científica. As conclusões de cada subgrupo foram referendadas em votação final com todos os participantes. Foi adotado como consensual as decisões que atingissem 70% ou mais de concordância entre os participantes. Este artigo apresenta as principais recomendações e conclusões para orientação aos profissionais brasileiros envolvidos com a infecção por H. pylori.

Do probiotics improve eradication response to Helicobacter pylori on standard triple or sequential therapy?

The standard triple therapy for the eradication of Helicobacter pylori consists of a combination of a proton pump inhibitor at a standard dose together with two antibiotics [amoxicillin 1000 mg plus either clarithromycin 500 mg or metronidazole 400 mg] all given twice daily for a period of 7-14 days. Recent reports have shown a dramatic decline in the rate of H. pylori eradication utilizing standard triple therapy from 95% down to 70-80%. Our study was designed to evaluate the effect of adding a probiotic as an adjuvant to common regimens used for H. pylori eradication. An open label randomized observational clinical study was designed to test three different regimens of H. pylori eradication treatment: Standard triple therapy with a concomitant probiotic added at the same time [n = 100], starting the probiotic for 2 weeks before initiating standard triple therapy along with the probiotic [n = 95], and the third regimen consists of the probiotic given concomitantly to sequential treatment [n = 76]. The three arms were compared to a control group of patients treated with the traditional standard triple therapy [n = 106]. The eradication rate for the traditional standard therapy was 68.9%, and adding the probiotic "Bifidus infantis" to triple therapy, led to a successful rate of eradication of 83% [P < 0.001]. Pre-treatment with 2 weeks of B. infantis before adding it to standard triple therapy increased the success rate of eradication to 90.5%. Similar improvement in eradication rate was noted when B. infantis was added as an adjuvant to the sequential therapy leading to an eradication rate of 90.8%. Adding B. infantis as an adjuvant to several therapeutic regimens commonly used for the eradication of H. pylori infection significantly improves the cure rates

Helicobacter pylori infection in India from a western perspective.

Helicobacter pylori is a common bacterial infectious disease whose manifestations predominately affect the gastrointestinal tract. India is the prototypical developing country as far as H. pylori infection is concerned and more than 20 million Indians are estimated to suffer from peptic ulcer disease. Considering the high level of medical research and of the pharmaceutical industry, one would expect that India would be the source of much needed information regarding new therapies and approaches that remain effective in the presence of antimicrobial resistance, new methods to reliably prevent reinfection, and the development of therapeutic and preventive vaccines. Here we discuss H. pylori as a problem in India with an emphasis on H. pylori infection as a serious transmissible infectious disease. We discuss the pros and cons of eradication of H. pylori from the entire population and come down on the side of eradication. The available data from India regarding antimicrobial use and resistance as well as the effectiveness of various treatments are discussed. Rigorous ongoing studies to provide current regional antibiotic resistance patterns coupled with data concerning the success rate with different treatment regimens are needed to guide therapy. A systematic approach to identify reliably effective (e.g., 90% or greater treatment success) cost-effective regimens is suggested as well as details of regimens likely to be effective in India. H. pylori is just one of the health care problems faced in India, but one where all the resources are on hand to understand and solve it.

Presencia de organismo asociados a helicobacter (HLO) después de 21 días de tratamiento en perros asintomáticos: un estudio preliminar / Presence of helicobacter like organisms after twenty one days of treatment in asympotomatic dogs: a preliminar study

La presencia de Organismos Asociados a Helicobacter (HLO), en el estomago de perros y gatos ha sido descrito previamente. El objetivo de este estudio fue evaluar la presencia de Organismos Asociados a Helicobacter, después de 21 días de tratamiento en perros asintomáticos. Siete perros fueron tratados durante 21 días con doxiciclina comercial en dosis 20mg/kg/día. Muestras de estomago fueron colectadas por gastroendoscopia. Secciones de tejido gástrico fueron procesadas, coloreadas con Hematoxilina y Eosina (H&E) y observadas en el microscopio óptico. Ninguno de los perros presento signos clínicos previos de enfermedad gastrointestinal. En el examen gastroendoscopico previo al tratamiento fue observada una mucosa gástrica normal en 1/7 perros, gastritis aguda superficial 3/7, gastritis crónica superficial 1/7, gastritis crónica atrófica 1/7 y gastritis erosiva ulcerosa 1/7. El estudio histopatológico revelo gastritis aguda superficial, erosión focal e hiperqueratosis con infiltración de linfocitos en la lamina propia. La presencia de bacterias tipo espiroquetas en el moco gástrico y en las glándulas fúndicas fue observada y asociada con lesiones gástricas. La evaluación gastroendoscopica después del tratamiento con doxiciclina revelo: 4/7 perros con mucosa gástrica normal, 2/7 con gastritis aguda superficial y 1/7 con gastritis crónica superficial. Los cortes histológicos de mucosa gástrica evidenciaron gastritis aguda superficial, erosión focal e hiperqueratosis focal infiltrado por linfocitos en la lámina propia. Ninguna muestra mostró bacterias tipo espiroquetas después del tratamiento con doxiciclina.Estos resultados nos permiten concluir que el tratamiento con doxiciclina es efectivo sobre la presencia de Organismos Asociados a Helicobacter en la mucosa gástrica de caninos

The presence of gastric Helicobacter-like organisms (HLO) in the stomach of dogs and cats has been known for many years, but the relationship between those organisms and gastric disease remains controversial. The objective of this study was to evaluate the presence of Helicobacter like organisms after twenty one days of treatment in asymptomatic dogs. Seven dogs were treated for 21 days with commercial doxycycline at a dose of 20mg/kg/day. Stomach samples were collected by gastroendoscopy from 7 dogs, before an after doxycycline treatment. Gastric tissue sections were prepared and stained with Hematoxilin & Eosin (H&E) for light microscopy. None of these dogs showed previous clinical signs of gastrointestinal disease. In the gastroendoscopy study after of doxycycline treatment we found a normal gastric mucosa in 1/7 dogs, acute superficial gastritis in 3/7, chronic superficial gastritis in 1/7, chronic atrophic gastritis 1/7 and chronic ulcer-erosive gastritis in 1/7. The histopathological study showed acute surface gastritis, focal erosion and hyperkeratosis with lymphocytes infiltration in the lamina propria. The presence of spirochetal shaped bacterias in the gastric mucus and fundus mucousglands were observed associated with gastric lesions. Gastroendoscopy after treatment with doxycycline reveled: 4/7 gastric mucosa normal, 2/7 superficial acute gastritis and 1/7 superficial chronic gastritis. Histopathology showed acute gastritis surface, erosion focal and hyperkeratosis focal infiltrated of lymphocytes in the lamina propria. None samples showed spiral shape bacterial after the treatment with doxyclyne. We conclude that doxycycline is effective for HLO on presence in gastric mucosa of dogs

Utilidad del tratamiento secuencial modificado con levofloxacina en la erradicación del Helicobacter pylori / Modified sequential treatment with levofloxacin in the eradication of Helicobacter pylori

Introducción: La infección por Helicobacter pylori, está asociada a múltiples complicaciones: gastritis crónica, úlcera gástrica y duodenal, cáncer gástrico y linfoma tipo MALT. Los niveles de erradicación y adherencia con la terapia estándar han declinado progresivamente en los últimos años. La terapia secuencial modificada podría ser una alternativa para mejorar su eficacia y la adherencia al tratamiento en vista de la alta resistencia actual a la claritromicina. Objetivos: Comparar la eficacia de la terapia triple secuencial estándar y la terapia triple secuencial modificada con levofloxacina para la erradicación de Helicobacter pylori. Materiales y Métodos: Se estudiaron 140 pacientes con infección por Helicobacter pylori comprobada por biopsia gástrica que fueron asignados en forma aleatorizada en dos grupos de tratamiento: Grupo de terapia secuencial estándar con omeprazol y amoxicilina por 5 días, seguido de omeprazol, claritromicina y metronidazol por 5 días adicionales. Grupo de terapia secuencial modificada con omeprazol y amoxicilina por 5 días, seguido de omeprazol, levofloxacina y metronidazol por 5 días adicionales. La erradicación se confirmó por biopsia gástrica posterior al tratamiento. Se realizó un cuestionario dirigido para evaluar la adherencia y los efectos secundarios en cada grupo. Resultados: Se evaluaron 70 pacientes en cada grupo. La tasa de erradicación y de abandono de tratamiento fue de 80% y 5,71% respectivamente en el grupo de terapia secuencial modificada comparando con 65,71% y 11,42% en el grupo de terapia secuencial estándar, siendo estadísticamente significativas las diferencias en ambos casos (p<0,05). Conclusiones: La terapia secuencial modificada con levofloxacina logra mayores tasas de erradicación y de adherencia al tratamiento del Helicobacter pylori cuando se compara con la terapia secuencial estándar.

Introduction: The infection by Helicobacter pylori, is associate with multiple complications: chronic gastritis, gastric and duodenal ulcer, gastric cancer and lymphoma type MALT. The levels of eradication and adherence with the standard therapy have declined progressively in the last years. The sequential modified therapy could be an alternative to improve his efficiency and the adherence to the treatment in view of the high current resistance to the clarithromycin. Aims: To compare the efficiency of the triple sequential standard therapy and the triple sequential therapy modified with levofloxacin for the eradication of Helicobacter pylori. Materials and Methods: 140 patients were studied by infection by Helicobacter pylori verified by gastric biopsy that they were assigned in randomized form in two groups of treatment: Group of sequential standard therapy with omeprazole and amoxicillin for 5 days, followed by omeprazole, clarithromycin and metronidazole for 5 additional days. Group of sequential therapy modified with omeprazole and amoxicillin for 5 days, followed by omeprazole, levofloxacin and metronidazole for 5 additional days. The eradication was confirmed by gastric biopsy later to the treatment. Was realized a questionnaire to evaluate the adherence and the side effects in every group. Results: 70 patients were evaluated in every group. The rate of eradication and suspension of treatment was 80% and 5,71 % respectively in the group of sequential modified therapy comparing with 65,71% and 11,42% in the group of sequential standard therapy, being statistically significant the differences in both cases (p <0,05). Conclusions: The sequential therapy modified with levofloxacin achieves major rates of eradication and of adherence to the treatment of the Helicobacter pylori when it is compared with the sequential standard therapy.